Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Determine the Effect of R1507 Plus Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) With Progressive Disease After Clinical Benefit to Second or Third Line Tarceva Monotherapy.

Next Previous
Trial Profile

An Open-Label Study to Determine the Effect of R1507 Plus Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) With Progressive Disease After Clinical Benefit to Second or Third Line Tarceva Monotherapy.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teprotumumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Roche

Most Recent Events

  • 02 Apr 2022 This trial has been completed in France (End Date: 26 April 2013) according to European Clinical Trials Database record.
  • 21 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
  • 07 Mar 2013 Planned end date changed from 1 Dec 2010 to 1 May 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top